Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients

Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2010, Pages 576-580

  Capone, Domenico ^a   Tarantino, Giovanni ^a   Polichetti, Giuliano ^a   Kadilli, Irket ^a   Sabbatini, Massimo ^b   Basile, Vincenzo ^a   Carrano, Rosa ^b   Nappi, Riccardo ^b   Federico, Stefano ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Allograft; Fluoroquinolones; Immunosuppressors; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; MOXIFLOXACIN; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PHARMACOKINETICS; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CYCLOSPORINE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUINOLINES; TACROLIMUS; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 77951181133     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009347869     Document Type: Article

References (29)

1. Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin North Am. 2001 ; 15: 521-549.
2. Charfeddine K., Zaghden S., Kharrat M., Kamoun K., Jarraya F., Hachicha J. Infectious complications in kidney transplant recipients: a single-center experience. Transplant Proc. 2005 ; 37: 2823-2825.
3. McLellan RA, Drobitch RK, Monshouwer M., Renton KW Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos. 1996 ; 24: 1134-1138.
4. Ruiz J. Mechanism of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003 ; 51: 1109-1117.
5. Mitscher L. Bacterial topoisomerase inhibitors: quinolone and pyridine antibacterial agents. Chem Rev. 2005 ; 105: 559-592.
6. Zhang L., Wei MJ, Zhao CY, et al. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008 ; 29: 1507-1514.
7. Guay DRP. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag. 2006 ; 2: 417-434.
8. Elbe DH, Chang SW Moxifloxacin-warfarin interaction: a series of five case reports. Ann Pharmacother. 2005 ; 39: 361-364.
9. Yildiz F., Kurtaran B., Cayli M., et al. A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve. Heart Vessels. 2008 ; 23: 286-288.
10. Carroll DN, Carroll DG Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother. 2008 ; 42: 680-685.
11. Avelox (moxifloxacin hydrochloride) [package insert]. Leverkusen Germany: Bayer HealthCare Pharmaceuticals ; 2008.
12. Morris RG, Saccoia NC, Ryall RG, et al. Specific enzyme-multiplied immunoassay and fluorescence polarization immunoassay for cyclosporine compared with cyclotrac[125I] radioimmunoassay. Ther Drug Monit. 1992 ; 4: 226-233.
13. Bartlomiejczyk I., Zochowska D., Sanko-Resmer J., et al. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. Transplant Proc. 2006 ; 38: 94-96.
14. Veyssier P., Voirot P., Begaud B., et al. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study). Med Mal Infect. 2006 ; 3: 505-512.
15. Campana C., Regazzi MB, Buggia I., et al. Clinically significant drug interactions with cyclosporine: an update. Clin Pharmacokinet. 1996 ; 30: 141-179.
16. Pea F., Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions: review. Clin Pharmacokinet. 2001 ; 40: 833-868.
17. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 ; 1: 96-121.
18. Borner K., Lode H. Biotransformation of certain gyrase inhibitors. Infection. 1986 ; 14 (suppl 1). S54 - S59.
19. Moise PA, Birmingham MC, Schentag JJ Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc). 2000 ; 36: 229-244.
20. Stass H., Nagelschmitz J., Moeller JG, et al. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther. 2004 ; 42: 23-29.
21. Federico S., Carrano R., Capone D., et al. Pharmacokinetic interaction between levofloxacin and cyclosporine or tacrolimus in kidney transplant recipients: cyclosporine, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006 ; 45: 169-175.
22. Doose DR, Walker SA, Chien SC, Williams RR, Nayak RK Levofloxacin does not alter cyclosporine disposition. J Clin Pharmacol. 1998 ; 38: 90-93.
23. Bonora S., Mondo L., Trentini A., et al. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. J Infect. 2008 ; 57: 78-81.
24. Duncan K., Barry Ceiii. Prospects for new intertubercular drugs. Curr Opin Microbiol. 2004 ; 7: 460-465.
25. Ziganshina LE, Squire SB Fluoroquinolones for treating tuberculosis: review. Cochrane Database Syst Rev. 2008 ;(1). CD004795.
26. Singh N., Paterson DL Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998 ; 27: 1266-1277.
27. Borrás-Blasco J., Conesa-García V., Navarro-Ruiz A., et al. Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia. Am J Med Sci. 2005 ; 330: 144-146.
28. Capone D., Aiello C., Santoro GA, et al. Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampycin, in organ transplanted patients. Int J Clin Pharm Res. 1996 ; 16: 73-76.
29. Spina E., Pisani F., Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet. 1996 ; 31: 198-214. (Pubitemid 26335906)